New antithrombotic drugs on the horizon

Expert Opinion on Investigational Drugs

Volumn 12, Issue 5, 2003, Pages 781-797

  Ruef, Johannes ^a   Katus, Hugo A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antithrombotic drugs; Coagulation; Factor Xa; Oral anticoagulant; Thrombin; Thrombosis; Tissue factor

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [1 [3 (4 PIPERIDINYL)PROPIONYL]NIPECOTOYLAMINO] 3 (3 PYRIDYL)PROPIONIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; DX 9065 A; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRUDIN DERIVATIVE; KFA 1829; LOW MOLECULAR WEIGHT HEPARIN; N (9 HYDROXY 9 FLUORENECARBOXY)PROLINE (4 AMINOCYCLOHEXYLMETHYL)AMIDE; NEW DRUG; OCTANOIC ACID DERIVATIVE; PD 313052; PROTEIN C; PROTHROMBIN; RPR 130737; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTIFICIAL EMBOLISM; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; FIBRINOLYSIS; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS;

FACTOR VII; FACTOR XA; FIBRINOLYTIC AGENTS; HEMOSTATICS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; THROMBIN; THROMBOEMBOLISM; THROMBOPLASTIN;

EID: 0037797327     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.5.781     Document Type: Review

References (137)

1. MURRAY CJ, LOPEZ AD: Mortalitiy by cause for eight regions of the world; global burden of disease study. Lancet (1997) 349:1269-1276.
2. ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71-86.
3. NEWBY LK, MCGUIRE DK: Oral platelet glycoprotein IIb/IIIa inhibition. Curr. Cardiol. Rep. (2000) 2:372-377.
4. TURPIE AG: Optimizing prophylaxis of venous thromboembolism. Semin. Thromb. Hemost. (2002) 28(Suppl. 2):25-32.
5. DAVIE EW, FUJIKAWA K, KISIEL W: The coagulation cascade: initiation, maintenance, and regulation. Biochemistry (1991) 30:10363-10370.
6. MUTCH NJ, ROBBIE LA, BOOTH NA: Human thrombi contain an abundance of active thrombin. Thromb. Haemost. (2001) 86:1028-1034.
7. EZEKOWITZ MD, NETREBKO PI: Anticoagulation in management of atrial fibrillation. Curr. Opin. Cardiol. (2003) 18:26-31.
8. VLASUK GP: Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation Factor Xa. Thromb. Haemost. (1993) 70:212-216.
9. TUSZYNSKI GP, GASIC TB, GASIC GJ: Isolation and characterization of antistasin. J. Biol. Chem. (1987) 262:9718-9723.
10. RIVERA TM: Oral delivery of heparin in combination with sodium N-(8[2-hydroxybenzoyl]amino)caprylate: pharmacologic considerations. Pharm. Res. (1997) 14:1830-1834.
11. MALKOV D, WANG HZ, DINH S, GOMEZ-ORELLANA I: Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate. Pharm. Res. (2002) 19:1180-1184.
12. PINEO GF, HULL RD, MARDER VJ: Orally active heparin and low-molecular-weight heparin. Curr. Opin. Pulm. Med. (2001) 7:344-8.
13. GONZE MD, SALARTASH K, STERNBERGH WC 3rd, BAUGHMAN RA, LEONE-BAY A, MONEY SR: Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation (2000) 101:2658-2661.
14. ANDERSON JA, FREDENBURGH JC, STAFFORD AR et al.: Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. J. Biol. Chem. (2001) 276:9755-9761.
15. FREDENBURGH JC, ANDERSON JA, WEITZ JI: Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin. Trends Cardiovasc. Med. (2002) 12:281-287.
16. SUNDARAM M, QI Y, SHRIVER Z, LIU D et al.: Rational design of low-molecular-weight hepatitis with improved in vivo activity. Proc. Natl. Acad. Sci. USA (2003) 100:651-656.
17. CHOAY J, PETITOU M, LORMEAU JC, SINAY P, CASU B, GATTI G: Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun. (1983) 116:492-499.
18. ERIKSSON BI, BAUER KA, LASSEN MR et al.: Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. (2001) 345:1298-1304.
19. TURPIE AGG, BAUER KA, ERIKSSON BJ et al.: Postoperative fondaparinux versus postoperative enoxaparin for the prevention of venous thromboembolism after elective hip-replacemetn surgery: a randomised double-blind trial. Lancet (2002) 359:1721-1726.
20. THE REMBRANDT INVESTIGATORS: Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. Circulation (2000) 102:2726-2731.
21. VAN DE WERF F: New data in treatment of acute coronary syndromes. Am. Heart J. (2001) 142(Suppl. 2):S16-S21.
22. BAUER KA: Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin. Thromb. Hemost. (2002) 28(Suppl. 2):15-24.
23. WALENGA JM, JESKE WP, FRAPAISE FX, BICK RL, FAREED J, SAMAMA MM: Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin. Investig. Drugs (2002) 11:397-407.
24. HERBERT JM, HERAULT JP, BERNAT A et al.: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood (1998) 91:4197-4205.
25. REITER M, BUCEK RA, KOCA N, HEGER J, MINAR E: Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul. Fibrinolysis (2003) 14:61-65.
26. HERAULT JP, BERNAT A, ROYE F et al.: Pharmacokinetics of new synthetic heparin mimetics. Thromb. Haemost. (2002) 87:985-989.
27. HERAULT JP, BERNAT A, GAICH C, HERBERT M: Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Thromb. Haemost. (2002) 87:238-244.
28. PORCARI AR, CHI L, LEADLEY R: Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors. Expert Opin. Investig. Drugs (2000) 9:1595-1600.
29. HERBERT JM, BERNAT A, DOL F, HERAULT JP, CREPON B, LORMEAU JC: DX 9065a a novel, synthetic, selective and orally active inhibitor of Factor Xa: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. (1996) 276:1030-1038.
30. MURAYAMA N, MCMAHON H, YOUNG CG et al.: Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose. Xenobiotica (2000) 30:515-521.
31. BECKER RC, YOUFU L, ALEXANDER JH, SPENCER F, ROBERTSON TL, KUNITADA S: DX-9065a, a novel direct Factor Xa antagonist stimulates release of tissue factor pathway inhibitor (TFPI) from human vascular endothelial cells. Circulation (2002) (Suppl. II):337 (Abstract).
32. SHIMBO D, OSENDE J, CHEN J et al.: Antithrombotic effects of DX-9065a, a direct Factor Xa inhibitor a comparative study in humans versus low molecular weight heparin. Thromb. Haemost. (2002) 88:733-738.
33. DYKE CK, BECKER RC, KLEIMAN NS et al.: First experience with direct Factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation (2002) 105:2385-2391.
34. PINTO DJ, ORWAT MJ, WANG S et al.: Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2′-(methylsulfonyl)- [1,1′biphenyl]-4-yl]-3-(trifluoromathyl)-1 pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation Factor Xa. J. Med. Chem. (2001) 44:566-578.
35. WONG PC, PINTO DJ, KNABB RM: Nonpeptide Factor Xa inhibitors: DPC423, a highly potent an orally bioavailable pyrazole antithrombotic agent. Cardiovasc. Drug Rev. (2002) 20:137-152.
36. WONG PC, CRAIN EJ, WATSON CA et al.: Nonpeptide Factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J. Pharmacol. Exp. Ther. (2002) 303:993-1000.
37. CHU V, BROWN K, COLUSSI D et al.: Pharmacological characterization of a novel Factor Xa inhibitor FXV673. Thromb. Res. (2001) 103:309-324.
38. GUERTIN KR, GARDNER CJ, KLEIN SI et al.: Optimization of the beta-aminoester class of Factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity Bioorg. Med. Chem. Lett. (2002) 12:1671-1674.
39. REBELLO SS, BENTLEY RG, MORGAN SR et al.: Antithrombotic efficacy of a novel Factor Xa inhibitor, FXV6 in a canine model of coronary artery thrombolysis. Br. J. Pharmacol. (2001) 133:1190-1198.
40. AHMED T: IDDB meeting report from the 17th International Society of Thrombosis and Haemostasis Congress 1999, Washington DC, USA. IDdb3 Report (1999) (338793).
41. CHU V, BROWN K, COLUSSI D et al.: In vitro characterization of a novel Factor Xa inhibitor, RPR 130737. Thromb. Res. (2000) 99:71-82.
42. LIGHT DR, GUILFORD WJ: Discovery of the Factor Xa inhibitor, ZK 807834 (CI-1031). Curr. Top. Med. Chem. (2001) 1:121-136.
43. CHI L, PEN YW, POTOCZAK R et al.: Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct Factor Xa inhibitor. Pharmacology (2002) 64:76-83.
44. POST JM, SULLIVAN ME, ABENDSCHEIN D, EWING J, HINCHMAN JW, LIGL DR: Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031). Thromb. Res. (2002) 105:347-352.
45. WONG PC, CRAIN EJ, KNABB RM et al.: Nonpeptide Factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J. Pharmacol. Exp. Ther. (2000) 295:212-218.
46. WONG PC, QUAN ML, CRAIN EJ, WATSON CA, WEXLER RR, KNABB RM: Nonpeptide Factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J. Pharmacol. Exp. Ther. (2000) 292:351-357.
47. NARASIMHAN S, KOSKI RA, BEAULIEU B et al.: A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol. Biol. (2002) 11:641-650.
48. NISHIDA H, MIYAZAKI Y, MUKAIHIRA T et al.: Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a Factor Xa inhibitor II. Substituent effect on biological activities. Chem. Pharm. Bull. (2002) 50:1187-1194.
49. HIRAYAMA F, KOSHIO H, KATAYAMA N et al.: The discovery of YM-60828: a potent, selective and orally-bioavailable Factor Xa inhibitor. Bioorg. Med. Chem. (2002) 10:1509-1523.
50. SEMPLE JE, LEVY OE, MINAMI NK, OWENS TD, SIEV DV: Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic P1-ketoamide moieties. Bioorg. Med. Chem. Lett. (2000) 10:2305-2309.
51. HAYASHI M, MATSUO A, NAKAMOTO H, AISAKA K: Antithrombotic effects of a synthetic inhibitor of activated Factor X, JTV-803, in animals. Eur. J. Pharmacol. (2001) 412:61-66.
52. WATERWORTH C: IDDB meeting report from the XIVth Annual World Congress of Pharmacology; July 2002, San Francisco, USA. IDdb3 Report (2002) (457377).
53. The IDdb reference report (460177): New drugs in the R&D pipeline. Pharma Japan (2002) 1806:1-20.
54. SONG Y, CLIZBE L, BHAKTA C et al.: Design and synthesis of Factor Xa inhibitors and their prodrugs. Bioorg. Med Chem. Lett. (2003) 13:297-300.
55. KAPLAN KL, FRANCIS CW: Direct thrombin inhibitors. Semin. Hematol. (2002) 39:187-196.
56. MATSUO T, KARIO K, KODAMA K, OKAMOTO S: Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Sem. Thromb. Hemost. (1992) 18:155-160.
57. HAUPTMANN J: Pharmacokinetics of an emerging new class of anticoagulant-antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur. J. Clin. Pharmacol. (2002) 57:751-758.
58. GLYNN O: The express study: preliminary results. Int. J. Clin. Pract. (2003) 57:57-59.
59. ERIKSSON BI, BERGQVIST D, KALEBO P et al.: Ximelagatran and melagartan compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet (2002) 360:1441-1447.
60. WAHLANDER K, LAPIDUS L, OLSSON CC et al.: Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb. Res. (2002) 107:93-99.
61. NOTEBERG D, BRANALT J, KVARNSTROM I et al.: New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. J. Med. Chem. (2000) 43:1705-1713.
62. HAUEL NH, NAR H, PRIEPKE H, RIES U, STASSEN JM, WIENEN W: Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. (2002) 45:1757-1766.
63. MUNGALL D: BIBR-1048 Boehringer Ingelheim. Curr. Opin. Investig. Drugs (2002) 3:905-907.
64. BUCKLE DR: IDdb meeting report from the IXth RSC-SCI Medicinal Chemistry Symposium 1997, Cambridge, UK. IDdb3 Report (1997) (263572).
65. KAKKAR S: New advances in a rapidly expanding blockbuster market. SMI Conference - Advances in Hypertension and Cardiovascular Therapeutics. IDdb3 Report (2002) (453507).
66. 3-Dimensional Pharmaceuticals, Inc. IDdb3 Report (2001) (Press release, 399111).
67. CHI L, MERTZ TE, ROGERS KL et al.: Antithrombotic effect of LB-30057 (CI-1029), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. J. Thromb. Thrombolysis (2001) 11:19-31.
68. McCLANAHAN TB, HICKS GW, IGNASIAK DP et al.: The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis. J. Thromb. Thrombolysis (2000) 10:277-284.
69. BERRY CN, LASSALLE G, LUNVEN C et al.: SSR182289A, a novel, orally active thrombin inhibitor in vitro profile and ex vivo anticoagulant activity. J. Pharmacol. Exp. Ther. (2002) 303:1189-1198.
70. GIARDINO EC, COSTANZO MJ, KAUFFMAN JA, LI QS, MARYANOFF BE, ANDRADE-GODRON P: Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor. Thromb. Res. (2000) 98:83-93.
71. ADANG AE, DE MAN AP, VOGEL GM et al.: Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics. J. Med. Chem. (2002) 45:4419-4432.
72. NORMAN P: IDDB meeting report from the Cutting Edge Approaches to Drug Design - RSC's Second Meeting, London, UK, 2002. IDdb3 Report (2002) (444796).
73. BRADY SF, STAUFFER KJ, LUMMA WC et al.: Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl-trans-4-aminocyclohexylmethyl amide (L-372, 460: coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J. Med. Chem. (1998) 41:401-406.
74. BRUNDISH D, BULL A. DONOVAN V et al: Design and synthesis of thrombin inhibitors: analogues of MD 805 with reduced stereogenicity and improved potency. J. Med. Chem. (1999) 42:4584-4603.
75. CUI JJ, ARALDI GL, REINER JE et al: Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bycyclic arginine surrogates. Bioorg. Med. Chem. Lett. (2002) 12:2925-2930.
76. Servier, following the XVIIIth ISTH meeting 2001, Paris, France. IDdb3 Report (2001) (Press release, 415369).
77. VitaResc Biotech AG. IDdb3 Report (2001) (Press release, 417532).
78. FRIEDERICH PW, KELLER TT, BIEMOND BJ et al.: Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor. Thromb. Haemost. (2000) 84:858-864.
79. Groupe Fournier. IDdb3 Report (1999) (Company comm., 347216).
80. GIRARD TJ, NICHOLSON NS: The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation. Curr. Opin. Pharmacol. (2001) 1:159-163.
81. BAJAJ MS, BAJAJ SP: Tissue factor pathway inhibitor: potential therapeutic applications. Thromb. Haemost. (1997) 78:471-477.
82. PEDERSON AH, NORDFANG O, NORRIS F et al.: Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor initiated coagulation reactions. J. Biol. Chem. (1990) 265:16786-16793.
83. KAMIKUBO Y, HAMURO T, MATSUDA J et al: Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin. Thromb. Haemost. (1996) 76:621-626.
84. ROQUE M, REIS ED, FUSTER V et al.: Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J. Am. Coll. Cardiol. (2000) 36:2303-2310.
85. YANG J, LEE GF, RIEDERER MA, KELLEY RF: Enhancing the antionagulant potency of soluble tissue factor mutants by increasing their affinity to Factor VIIa. Thromb. Haemost. (2002) 87:450-458.
86. HIMBER J, REFINO CJ, BURCKLEN L, ROUX S, KIRCHHOFER D: Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb. Haemost. (2001) 85:475-481.
87. KITAZAWA T, ASADA Y, KUMAGAI E et al.: Humanized anti-human tissue factor antibody prevents both arterial and venous thrombosis in non-human primates. Circulation (2002) (Suppl. II):596 (Abstract).
88. DENNIS MS, EIGENBROT C, SKELTON NJ et al.: Peptide exosite inhibitors of Factor VIIa as anticoagulants Nature (2000) 404:465-470.
89. DENNIS MS, ROBERGE M, QUAN C, LAZARUS RA: Selection and characterization of a new class of peptide exosite inhibitors of coagulation Factor VIIa. Biochemistry (2001) 40:9513-9521.
90. DUGGAN BM, DYSON HJ, WRIGHT PE: Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Eur. J. Biochem. (1999) 265:539-548.
91. BUDDAI SK, TOULOKHONOVA L, BERGUM PW, VLASUK GP, KRISHNASWAMY S: Nematode anticoagulant protein c2 reveals a site on Factor Xa that is important for macromolecular substrate binding to human prothrombinase. J. Biol. Chem. (2002) 277:26689-26698.
92. LEE A, AGNELLI G, BULLER H et al.: Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation (2001) 3:74-78.
93. CORVAS INTERNATIONAL CORP: NAPc2 safe and well tolerated in a Phase IIa PTCA trial. IDdb3 Report (2001) (Press release, 432360).
94. RAI R, KOLESNIKOV A, YOUNG WB, SHRADER WD, LIU L, ENRIQUEZ P: Synthesis and pharmacokinetics of novel anticoagulants. 224th American Chemical Society Conference, Boston, MA, USA (2000).
95. TAKEHANA S, KAYAHARA T, TASHIRO K etal.: Antithrombotic effects of AXC4845, a newly synthezised and selective Factor VIIa inhibitor, in the rat thrombosis models. Thromb. Haemost. (2001) 86(Suppl.):P1393 (Abstract).
96. SO L: IDDB meeting report from the XVIIIth ISTH meeting 2001, Paris, France. IDdb Report (2001) (415130).
97. HUBER K: Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J. Thromb. Thombolysis (2001) 11:183-193.
98. YAMADA Y, IZAWA H, ICHIHARA S et al.: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N. Engl. J. Med. (2002) 347:1916-1923.
99. CHARLTON PA, FAINT RW, BENT F et al.: Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb. Haemost. (1996) 75:808-815.
100. RUPIN A, MARTIN F, VALLEZ MO, BONHOMME E, VERBEUREN TJ: Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of platelet-rich thrombus in rat mesenteric arterioles. Thromb. Haemost. (2001) 86:1528-1531.
101. MOHRI M, SUGIMOTO E, SATA M, ASANO T: The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation - a comparison with other anticoagulants. Thromb. Haemost. (1999) 82:1687-1693.
102. GRIFFIN JH, ZLOKOVIC B, FERNANDEZ JA: Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol. (2002) 39:197-205.
103. JACKSON CV, BAILEY BD, SHETLER TJ: Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis. J. Pharmacol. Exp. Ther. (2000) 295:967-971.
104. SAKAMOTO T, OGAWA H, TAKAZOE K et al.: Effects of human plasma-derived activated protein C on thrombolytic therapy in patients with acute myocardial infarction; comparison with unfractionated heparin. Circulation (2002) (Suppl. II):3104 (Abstract).
105. SINGH I, SMITH A, VANZIELEGHEM B et al: Antithrombotic effects of controlled inhibition of Factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood (2002) 99:3235-3240.
106. CURACYTE AG. IDdb3 Report (Press release, 458876).
107. WALL D, DOUGLAS S, FERROV, COWDEN W, PARISH C: Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb. Res. (2001) 103:325-335.
108. DEMIR M, IQBAL O, HOPPENSTEADT PA et al.: Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin. Appl. Thromb. Hemost. (2001) 7:131-140.
109. RUEF J, PETER K, NORDT TK, RUNGE MS, KUBLER W, BODE C: Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. thromb. Haemost. (1999) 82(Suppl. 1):32-37.
110. BURGAUD JL, ONGINI E, DEL SOLDATO P: Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann. NY Acad. Sci. (2002) 962:360-371.
111. NicOx SA, on drug development pipeline (NCX-5022). IDdb3 Report (2002) (Company Comm., 453178).
112. HOWARD PA: Aspirin resistance. Ann. Pharmacother. (2002) 36:1620-1624.
113. PIENIASZEK HJ Jr, SY SK, EBLING W et al.: Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J. Clin. Pharmacol. (2002) 42:738-753.
114. SEREBRUANY VL, MALININ AI, O'CONNOR CM, GURBEL PA: Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease. Circulation (2002) (Suppl. II):2436 (Abstract).
115. DAMIANO BP, MITCHELL JA, GIARDINO E et al: Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb. Res. (2001) 104:113-126.
116. SCHWARZ M, ROETTGEN P, LITTLE M et al.: Generation of human, activation-specific single chain antibodies directed against platelet integrin receptor GPIIb/IIIa. Circulation (2002) (Suppl. II):390 (Abstract).
117. KAGEYAMA S, YAMAMOTO H, YOSHIMOTO R: Anti-human von Willebrand factor monoclonal antibody AjvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2303-2308.
118. KAGEYAMA S, MATSUSHITA J, YAMAMOTO H: Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur. J. Pharmacol. (2002) 443:143-149.
119. GUREVITZ O, ELDAR M, SKUTELSKY E etal.: S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model. Thromb. Haemost. (2000) 84:912-917.
120. NIESWANDT B, SCHULTE V, BERGMEIER W et al.: Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J. Exp. Med. (2001) 193:459-469.
121. SUGIDACHI A, ASAI F, YONEDA K et al.: Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br. J. Pharmacol. (2001) 132:47-54.
122. GOTO S, TAMURA, N, ETO K, IKEDA Y, HANDA S: Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation (2002) 105:2531-2536.
123. SCARBOROUGH RM, LAIBELMAN AM, CLIZBE LA et al.: Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y(12)). Bioorg. Med. Chem. Lett. (2001) 11:1805-1808.
124. BAURAND A, RABOISSON P, FREUND M et al.: Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur. J. Pharmacol. (2001) 412:213-221.
125. ANDRADE-GORDON P, MARYANOFF BE, DERIAN CK et al.: Design, synthesis, and biological characterization of a peptide mimetic antagonist for a tethered-ligand receptor. Proc. Natl. Acad. Sci. USA (1999) 96:12257-12262.
126. COVIC L, MISRA M, BADAR J, SINGH C, KULIOPULOS A: Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. (2002) 8:1161-1165.
127. PRIETO AR, MA H, HUANG R et al.: Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. Cardiovasc. Res. (2002) 53:984-992.
128. MOMI S, EMERSON M, PAUL W et al.: Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur. J. Pharmacol. (2000) 397:177-185.
129. FIORUCCI S, MENCARELLI A, MENEGUZZI A et al.: NCX-4016(NO-Aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo. Circulation (2002) 106:3120-3125.
130. GUREVICH VS, LOMINADZE DG, ADEAGBO AS et al: Antithrombotic and vasorelaxant properties of a novel synthetic RGD peptide containing nitric oxide. Pharmacology (1997) 55:1-9.
131. GRESELE P, AGNELLI G: Novel approaches to the treatment of thrombosis. Trends Pharmacol. Sci. (2002) 23:25-32.
132. VAN AKEN H, BODE C, DARIUS H et al.: Anticoagulation: the present and future. Clin. Appl. Thromb. Hemost. (2001) 7:195-204.
133. WEITZ JI, HIRSH J: New anticoagulant drugs. Chest (2001) 119(Suppl.):95S-107S.
134. PATRONO C, RENDA G: Platelet activation and inhibition in unstable coronary syndromes. Am. J. Cardiol. (1997) 80:E17-E20.
135. VAN ES RF, JONKER JJ, VERHEUGT FW, DECKERS JW, GROBBEE DE: Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet (2002) 360:109-113.
136. LENZ TL, HILLEMAN DE: Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann. Pharmacother. (2000) 34:1283-1290.
137. READ ML, FARROW PJ, SEYMOUR LW: Emerging developments in RNA therapeutics. Exp. Opin. Ther. Targets (2003) 7:299-303